Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: February 10, 2004
Last updated: March 9, 2010
Last verified: March 2010